AbbVie to present IBD data at UEGW 2026
The release headline says data on long-term clinical and endoscopic outcomes for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) across inflammatory bowel disease will be highlighted at UEGW 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.